WallStreetZenWallStreetZen

NASDAQ: CORT
Corcept Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CORT past earnings growth

How has CORT's earnings growth performed historically?
Company
7.37%
Industry
52.77%
Market
104.85%
CORT's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
CORT's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
CORT's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

CORT past revenue growth

How has CORT's revenue growth performed historically?
Company
20.04%
Industry
149.51%
Market
17.15%
CORT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CORT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CORT's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CORT earnings and revenue history

Current Revenue
$482.4M
Current Earnings
$105.5M
Current Profit Margin
21.9%

CORT Return on Equity

Current Company
22%
Current Industry
-63.5%
Current Market
188%
CORT's Return on Equity (22%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CORT announces earnings.

CORT Return on Assets

Current Company
17.9%
Current Industry
2.9%
CORT is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CORT Return on Capital Employed

Current Company
20.63%
Current Industry
19.5%
CORT's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CORT vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CORT$482.38M$109.00M$105.50M+13.93%+9.43%
APGE$0.00-$83.90M-$83.99MN/AN/A
ARVN$78.50M-$359.70M-$367.30M+40.53%N/A
CGON$204.00k-$55.48M-$67.80M-85.97%N/A
MRUS$43.95M-$163.72M-$154.94M+2.75%N/A
View Top Biotech Stocks

CORT earnings dates

Next earnings date
May 1, 2024

Corcept Therapeutics Earnings & Revenue FAQ

What were CORT's earnings last quarter?

On Invalid Date, Corcept Therapeutics (NASDAQ: CORT) reported Q4 2023 earnings per share (EPS) of $0.30, up 100% year over year. Total Corcept Therapeutics earnings for the quarter were $31.14 million. In the same quarter last year, Corcept Therapeutics's earnings per share (EPS) was $0.15.

If you're new to stock investing, here's how to buy Corcept Therapeutics stock.

What was CORT's earnings growth in the past year?

As of Q2 2024, Corcept Therapeutics's earnings has grown 7.37% year over year. This is 45.4 percentage points lower than the US Biotechnology industry earnings growth rate of 52.77%. Corcept Therapeutics's earnings in the past year totalled $105.50 million.

What is CORT's earnings date?

Corcept Therapeutics's earnings date is Invalid Date. Add CORT to your watchlist to be reminded of CORT's next earnings announcement.

What was CORT's revenue last quarter?

On Invalid Date, Corcept Therapeutics (NASDAQ: CORT) reported Q4 2023 revenue of $135.41 million up 31.39% year over year. In the same quarter last year, Corcept Therapeutics's revenue was $103.06 million.

What was CORT's revenue growth in the past year?

As of Q2 2024, Corcept Therapeutics's revenue has grown 20.04% year over year. This is 129.48 percentage points lower than the US Biotechnology industry revenue growth rate of 149.51%. Corcept Therapeutics's revenue in the past year totalled $482.38 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.